helpline 01494 601 400
18 July 2012

Zonegran (zonisamide) licensed as monotherapy

Pharmaceutical company Eisai has announced that its anti-epileptic drug Zonegran (zonisamide) has been given a licence for use as monotherapy. This means that it can now be used on its own in the treatment of epilepsy. Zonegran is used for the treatment of focal seizures with or without secondary generalisation.